[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1117990T1 - Μορφες 5-αζακιτιδινης - Google Patents

Μορφες 5-αζακιτιδινης

Info

Publication number
CY1117990T1
CY1117990T1 CY20161100901T CY161100901T CY1117990T1 CY 1117990 T1 CY1117990 T1 CY 1117990T1 CY 20161100901 T CY20161100901 T CY 20161100901T CY 161100901 T CY161100901 T CY 161100901T CY 1117990 T1 CY1117990 T1 CY 1117990T1
Authority
CY
Cyprus
Prior art keywords
forms
azakitidine
azacytidine
preparing
represented
Prior art date
Application number
CY20161100901T
Other languages
English (en)
Inventor
Dumitru Ionescu
Peter Blumbergs
Lee Alani Selvey
Original Assignee
Celgene International Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32987557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1117990(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene International Sarl filed Critical Celgene International Sarl
Publication of CY1117990T1 publication Critical patent/CY1117990T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση παρέχει καινοτομικές πολυμορφικές και ψευδοπολυμορφικές κρυσταλλικές μορφές 5-αζακιτιδίνης, μαζί με μεθόδους παρασκευής αυτών των μορφών, όπου η 5-αζακιτιδίνη αντιπροσωπεύεται από τον τύπο (I). Η εφεύρεση περιλαμβάνει επίσης φαρμακευτικές συνθέσεις που περιέχουν τις εν λόγω μορφές.
CY20161100901T 2003-03-17 2016-09-13 Μορφες 5-αζακιτιδινης CY1117990T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/390,578 US6887855B2 (en) 2003-03-17 2003-03-17 Forms of 5-azacytidine
PCT/US2004/007895 WO2004082619A2 (en) 2003-03-17 2004-03-16 Forms of 5-azacytidine

Publications (1)

Publication Number Publication Date
CY1117990T1 true CY1117990T1 (el) 2017-05-17

Family

ID=32987557

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161100901T CY1117990T1 (el) 2003-03-17 2016-09-13 Μορφες 5-αζακιτιδινης
CY20171100369T CY1118805T1 (el) 2003-03-17 2017-03-24 Νεες μορφες 5-αζακιτιδινης

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20171100369T CY1118805T1 (el) 2003-03-17 2017-03-24 Νεες μορφες 5-αζακιτιδινης

Country Status (11)

Country Link
US (7) US6887855B2 (el)
EP (5) EP1610784B1 (el)
CY (2) CY1117990T1 (el)
DK (2) DK2258711T3 (el)
ES (2) ES2621531T3 (el)
HU (2) HUE030717T2 (el)
LT (1) LT1610784T (el)
PL (2) PL1610784T3 (el)
PT (2) PT2258711T (el)
SI (2) SI2258711T1 (el)
WO (1) WO2004082619A2 (el)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US6887855B2 (en) * 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
EP2644614A3 (en) 2007-01-11 2014-02-26 IVAX Pharmaceuticals s.r.o. Solid state forms of 5-azacytidine and processes for preparation thereof
WO2009016617A2 (en) * 2007-08-02 2009-02-05 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
US8399420B2 (en) * 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof
JP2011505336A (ja) * 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
NZ623495A (en) * 2008-05-15 2015-08-28 Celgene Corp Oral formulations of cytidine analogs and methods of use thereof
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
WO2010017547A1 (en) * 2008-08-08 2010-02-11 Scinopharm Taiwan Ldt. Process for making 5-azacytosine nucleosides and their derivatives
WO2010111172A1 (en) 2009-03-23 2010-09-30 Ambit Biosciences Corporation Methods of treatment using combination therapy
WO2010129211A2 (en) * 2009-04-27 2010-11-11 Dr. Reddy's Laboratories Ltd. Preparation of decitabine
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
EP2295530B2 (en) * 2009-09-14 2019-04-17 The Procter & Gamble Company Detergent composition
EP2521913A4 (en) * 2010-01-08 2013-05-15 Agency Science Tech & Res METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
JP2014503597A (ja) * 2011-01-31 2014-02-13 セルジーン コーポレイション シチジンアナログの医薬組成物及びその使用方法
SG193622A1 (en) * 2011-03-31 2013-11-29 Celgene Internat Sarl Systhesis of 5-azacytidine
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
AU2012312308B2 (en) 2011-09-23 2015-11-19 Celgene Corporation Romidepsin and 5-azacitidine for use in treating lymphoma
MX2014003591A (es) 2011-09-26 2014-09-08 Celgene Corp Terapia de combinacion para canceres quimiorresistentes.
EP2773360B1 (en) 2011-11-03 2018-02-28 Millennium Pharmaceuticals, Inc. Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
WO2014076616A2 (en) * 2012-11-19 2014-05-22 Shilpa Medicare Limited Formulations of 5-azacytidine
US9765108B2 (en) 2012-11-19 2017-09-19 Shilpa Medicare Limited Formulation of 5-azacytidine
US9968627B2 (en) 2013-03-26 2018-05-15 Celgene Corporation Solid forms comprising 4-amino-1-β-D-ribofuranosyl-1,3,5-triazin-2(1H)-one and a coformer, compositions and methods of use thereof
CN103450303A (zh) * 2013-09-04 2013-12-18 重庆泰濠制药有限公司 阿扎胞苷晶型a、阿扎胞苷晶型b及其制备方法
WO2016029004A1 (en) 2014-08-22 2016-02-25 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
US20160095925A1 (en) * 2014-10-01 2016-04-07 Cadila Healthcare Limited Stable formulation of azacitidine or salts thereof and their process for preparation
GB2542881B (en) * 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
UA123400C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
BR112018007447B1 (pt) 2015-10-15 2023-12-05 Celgene Corporation Uso de 2-metil-1-[(4-[6-(trifluorometil)piridin-2-il]-6-{[2- (trifluorometil) piridin-4-il]amino}-1,3,5-triazin-2-il)amino]propan2-ol e composição farmacêutica compreendendo o referido composto
CN111278465A (zh) 2017-08-01 2020-06-12 德国癌症研究中心 mIDH1抑制剂和DNA低甲基化剂（HMA）的组合
CN107827944B (zh) * 2017-11-02 2020-11-24 北京满格医药科技有限公司 一种阿扎胞苷单晶的制备方法
CN109988207B (zh) * 2017-12-29 2022-01-04 江苏豪森药业集团有限公司 阿扎胞苷晶型的制备方法
CN116059404A (zh) 2018-06-11 2023-05-05 加利福尼亚大学董事会 用以治疗眼睛疾病的脱甲基化
CN110642901A (zh) * 2019-11-11 2020-01-03 扬子江药业集团有限公司 阿扎胞苷甲醇化物及其制备方法和药物组合物、用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1050899A (el) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
US5700640A (en) * 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5872104A (en) * 1994-12-27 1999-02-16 Oridigm Corporation Combinations and methods for reducing antimicrobial resistance
TW513409B (en) * 1996-06-07 2002-12-11 Eisai Co Ltd Polymorphs of donepezil hydrochloride
KR100398923B1 (ko) * 1996-10-16 2003-09-19 아이씨엔 파마슈티컬스, 인코포레이티드 모노시클릭 ｌ-누클레오시드, 이의 유사체 및 이들의 용도
EP1182204B1 (en) * 1999-06-03 2004-04-07 Eisai Co., Ltd. Crystals of carbapenem derivatives and pharmaceutical preparations for injection
ES2253233T3 (es) 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
HUP0302929A3 (en) * 2000-09-07 2004-10-28 Kaneka Corp Methods for crystallization of hydroxycarboxylic acids
WO2002070518A1 (en) * 2001-03-01 2002-09-12 Triangle Pharmaceuticals, Inc. Polymorphic and other crystalline forms of cis-ftc
US7772197B2 (en) * 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
WO2004041195A2 (en) 2002-10-31 2004-05-21 Supergen, Inc. Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
WO2004069796A2 (en) 2003-02-03 2004-08-19 Teva Pharmaceutical Industries Ltd. Process for producing levetiracetam
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
CN101856348A (zh) * 2003-08-29 2010-10-13 斯隆-凯特林癌症研究所 联合治疗癌症的方法
US7192781B2 (en) * 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060063735A1 (en) * 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
US20060069060A1 (en) * 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20080057086A1 (en) * 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
EP2644614A3 (en) 2007-01-11 2014-02-26 IVAX Pharmaceuticals s.r.o. Solid state forms of 5-azacytidine and processes for preparation thereof
EP2114152A1 (en) * 2007-01-25 2009-11-11 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
WO2009016617A2 (en) 2007-08-02 2009-02-05 Chemagis Ltd. Stable highly pure azacitidine and preparation methods therefor
EP2048151A1 (en) * 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JP2011505336A (ja) * 2007-11-01 2011-02-24 セルジーン コーポレイション 骨髄異形成症候群治療のためのシチジンアナログ
NZ623495A (en) * 2008-05-15 2015-08-28 Celgene Corp Oral formulations of cytidine analogs and methods of use thereof
EP2321302B1 (en) * 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
CN102171233A (zh) * 2008-08-06 2011-08-31 西科尔公司 制备氮杂胞苷中间体的方法
WO2010017547A1 (en) * 2008-08-08 2010-02-11 Scinopharm Taiwan Ldt. Process for making 5-azacytosine nucleosides and their derivatives
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) * 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina

Also Published As

Publication number Publication date
US6887855B2 (en) 2005-05-03
PL1610784T3 (pl) 2017-02-28
EP2258711B1 (en) 2017-01-18
US8614313B2 (en) 2013-12-24
ES2592287T3 (es) 2016-11-29
US20130059810A1 (en) 2013-03-07
US20040186065A1 (en) 2004-09-23
ES2621531T3 (es) 2017-07-04
EP2258710A1 (en) 2010-12-08
HUE033508T2 (en) 2017-12-28
WO2004082619A3 (en) 2005-05-26
EP2258710B1 (en) 2016-10-19
EP2270023B1 (en) 2016-06-15
PT1610784T (pt) 2016-09-23
US20050137150A1 (en) 2005-06-23
WO2004082619A2 (en) 2004-09-30
US20060247189A1 (en) 2006-11-02
US8513406B2 (en) 2013-08-20
SI2258711T1 (sl) 2017-08-31
US7772199B2 (en) 2010-08-10
HUE030717T2 (en) 2017-05-29
EP2270022B1 (en) 2016-06-29
US9192620B2 (en) 2015-11-24
EP1610784A4 (en) 2007-11-07
PT2258711T (pt) 2017-03-30
DK2258711T3 (en) 2017-04-24
US7078518B2 (en) 2006-07-18
EP2270022A1 (en) 2011-01-05
US20140107058A1 (en) 2014-04-17
EP2270023A1 (en) 2011-01-05
EP2258711A2 (en) 2010-12-08
EP2258711B9 (en) 2017-12-27
PL2258711T3 (pl) 2017-08-31
US20130059809A1 (en) 2013-03-07
US20100298253A1 (en) 2010-11-25
EP1610784B1 (en) 2016-07-06
CY1118805T1 (el) 2018-01-10
LT1610784T (lt) 2016-10-25
EP2258711A3 (en) 2011-03-30
DK1610784T3 (en) 2016-09-12
US8779117B2 (en) 2014-07-15
SI1610784T1 (sl) 2017-01-31
EP1610784A2 (en) 2006-01-04

Similar Documents

Publication Publication Date Title
CY1117990T1 (el) Μορφες 5-αζακιτιδινης
CY1114213T1 (el) Μεθοδοι απομονωσης κρυσταλλικης μορφης ι της 5-αζακυτιδινης
CY1111876T1 (el) Νεες πυρρολες με υπολiπiδaiμiκες και υποχοληστερολαιμικες δραστικοτητες, μεθοδος για την παρασκευη αυτων και φαρμακευτικες συνθεσεις που τις περιεχουν και η χρηση αυτων στην ιατρικη
CY1109886T1 (el) Καινοφανεις ενωσεις ως αντι-φλεγμονωδεις, ανοσοτροποποιητικοι και αντι υπερπλαστικοι παραγοντες
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
CY1105162T1 (el) Ενωσεις και η χρηση τους ως αναστολεις 5-ητ
CY1118658T1 (el) Συνθεση 18f-ραδιοεπισημασμενων στυρυλοπυριδινων απο τοσυλικες προδρομες ενωσεις και σταθερες φαρμακευτικες συνθεσεις αυτων
CY1119077T1 (el) Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
CY1107839T1 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
CY1106989T1 (el) Ενεργοποιητες γλυκοκινασης τυπου 5-υποκατεστημενης πυραζινης ή πυριδινης
CY1113519T1 (el) Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης
NO20072965L (no) Potentiatorer av glutamatreceptorer
EA200601002A1 (ru) 6-алкенил и 6-фенилалкил замещённые 2-хинолиноны и 2-хиноксалиноны в качестве ингибиторов поли(адф-рибоза) полимеразы
GB0100889D0 (en) Compounds
CY1114767T1 (el) Ν,ν-υποκατεστημενες ενωσεις 3-αμινοπυρρολιδινης χρησιμες ως αναστολεις επαναπροσληψης μονοαμινων
CY1110738T1 (el) Παραγωγα aminoαλκυλβενζοϋλ-βενζοφουραν ή βενζοθειοφαιν, μεθοδος παρασκευης τους και συνθεσεις που τα περιεχουν
CY1105784T1 (el) Εκδοχα της πιπepαζινυλακυλπιπepιδινης η παρασκευη τους και η εφαρμογη τους στη θepαπευτικη
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
CY1106716T1 (el) 4-υποκαθισταμενα παραγωγα πιπεριδινης
CY1113257T1 (el) Παραγωγα βενζυλοπιπεραζινης τα οποια ειναι χρησιμα στη θεραπεια γαστρεντερικων διαταραχων
DK1456212T3 (da) 6-aminomorphinanderivater, fremgangsmåder til fremstilling heraf og disses anvendelse